Form 4: Vir Biotechnology, Inc. (VIR), Scangos George A, transaction 02/17/2022

Summary

A Form 4 for George A. Scangos, a director and the President and CEO of Vir Biotechnology, Inc. (VIR), reporting two sales of common stock. On 02/17/2022, 10,024 shares were sold at $31.9308 to cover tax withholding on vested restricted stock units, and on 02/18/2022, 17,726 shares were sold at a weighted average of $30.6501 under a Rule 10b5-1 trading plan adopted December 24, 2021. Direct holdings after the sales were 112,989 shares. The form also lists indirect holdings, including 3,598,559 shares owned by Scangos as Trustee of the Scangos-Wilson Family Trust and shares in other family trusts. Howard Horn signed as Attorney-in-Fact on 02/22/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * SCANGOS GEORGE A (Last) (First) (Middle) C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 (Street) SAN FRANCISCO CA 94158 (City) (State) (Zip) | SCANGOS GEORGE A | (Last) | (First) | (Middle) | C/O VIR BIOTECHNOLOGY, INC. | 499 ILLINOIS STREET, SUITE 500 | SAN FRANCISCO | CA | 94158 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Vir Biotechnology, Inc. [ VIR ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) President and CEO | X | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | President and CEO
3. Date of Earliest Transaction
 (Month/Day/Year) 02/17/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 02/17/2022 | S (1) | 10,024 | D | $ 31.9308 | 130,715 | D
Common Stock | 02/18/2022 | S (2) | 17,726 | D | $ 30.6501 (3) | 112,989 | D
Common Stock | 3,598,559 | I | See footnote (4)
Common Stock | 61,660 | I | See footnote (5)
Common Stock | 877,135 | I | See footnote (6)
Common Stock | 61,660 | I | See footnote (7)
Common Stock | 877,135 | I | See footnote (8)
Common Stock | 115,000 | I | See footnote (9)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Explanation of Responses:
1. Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
2. Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 24, 2021.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.
5. The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
6. The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
7. The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
8. The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
9. The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.
Remarks:
/s/ Howard Horn, Attorney-in-Fact | 02/22/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_VIR_4_filed2022-02-22_0001209191-22-011756.xml

Size

20,575 bytes

SHA-256

dac0e04108c3758aeab1f56466fff86279579e710a87a56237d7a84edc38283d

Our copy

SEC_VIR_4_filed2022-02-22_0001209191-22-011756.xml

Original

www.sec.gov